References
1. Oldham R.K. Biological response modifiers. J Natl Cancer Inst. 1983;70:789–796.
2. Coley W.B. The treatment of inoperable sarcoma with the mixed toxins of erysipelas and Bacillus prodigiousis. Immediate and final results in 140 cases. J Am Med Assoc. 1898;31:389–395. Coley W.B. The treatment of inoperable sarcoma with the mixed toxins of erysipelas and Bacillus prodigiousis. Immediate and final results in 140 cases. J Am Med Assoc. 1898;31:456–465.
3. Jaeckle K.A., Mittelman A., Hill F.H. Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. J Clin Oncol. 1990;8:1408–1418. doi: 10.1200/JCO.1990.8.8.1408.
4. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (Lond.) 1975;256:495–497. doi: 10.1038/256495a0.
5. Quesada J.R., Hawkins M., Horning S. Cooperative phase I–II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med. 1984;77:427–432. doi: 10.1016/0002-9343(84)90097-4.
6. Dinarello C.A. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med. 1984;311:1413–1418. doi: 10.1056/NEJM198411293112205.
7. Ruef C., Coleman D.L. Granulocyte-macrophage colony-stimulating factor: pleotropic cytokine with potential clinical usefulness. Rev Infect Dis. 1990;12:41–62. doi: 10.1093/clinids/12.1.41.
8. Rusthoven J. The potential role of recombinant hematopoietic colony-stimulating factors in preventing infections in the immunocompromised host. Can J Infect Dis. 1991;2:74–88. doi: 10.1155/1991/782768.
9. Haranaka K. Traditional Chinese medicines as biological response modifiers. Mol Biother. 1989;1:175–179.
10. Bone R.C. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457–469. doi: 10.7326/0003-4819-115-6-457.
11. Sternberg E.M. mederator. The stress response and the regulation of inflammatory disease. Ann Intern Med. 1992;117:854–866. doi: 10.7326/0003-4819-117-10-854.
12. Dunn H.A., Powell M.L., Meitin C., Small P.A., Jr. Virus infection as a stressor: the influenza virus elevates plasma concentrations of corticosterone, and brain concentrations of MHPG and tryptophan. Physiol Behav. 1989;45:591–594. doi: 10.1016/0031-9384(89)90078-4.
13. Edwards C.K., 3rd, Yunger L.M., Lorence R.M., Dantzer R., Kelley K.W. ed 3. Vol. 88. 1991. The pituitary gland is required for protection against lethal effects of Salmonella typhimurium; pp. 2274–2277. (Proc Natl Acad Sci).
14. Catania A., Manfredi M.G., Airaghi I., Vivirito M.C., Milazzo F., Zanussi C. Evidence of impairment of the immune-adrenal circuit in patients with acquired immunodeficiency syndrome. Horm Metab Res. 1990;22:597–598. doi: 10.1055/s-2007-1004982.
15. Wilder R. Mechanisms of neuroendocrine effects on inflammation and the immune response. In: Sternberg E.M., editor. moderator. The stress response and the regulation of inflammatory disease. Vol. 117. 1992. pp. 854–866. (Ann Intern Med).
16. Tazi A., Nioche S., Chastre J., Smiejan J.M., Hance A.J. Spontaneous release of granulocyte colony-stimulating factor (G-CSF) by alveolar macrophages in the course of bacterial pneumonia and sarcoidosis: endotoxin-dependent and exotoxin-independent G-CSF release by cells recovered by bronchoalveolar lavage. Am J Respir Cell Mol Biol. 1991;4:140–147. doi: 10.1165/ajrcmb/4.2.140.
17. Roilides E., Walsh T.J., Pizzo P.A., Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis. 1991;163:579–583. doi: 10.1093/infdis/163.3.579.
18. Nelson S., Bagby G., Anderesen J., Shellito J., Summer W. Intratracheal granulocyte colony-stimulating factor enhances systemic and pulmonary host defences. Am Rev Respir Dis. 1991;143:S398.
19. Petrak R.A., Balk R.A., Bone R.C. Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin. 1989;5:303–314.
20. Balk R.A., Jacobs R.F., Tryka F., Townsend J.W., Walls R.C., Bone R.C. Effects of ibuprofen on neutrophil function and acute lung injury in canine endotoxin schock. Crit Care Clin. 1988;16:1121–1127. doi: 10.1097/00003246-198811000-00008.
21. Shalaby M.R., Aggarwal B.B., Rinderknect E., Svedersky L.P., Finkle B.S., Palladino M.A., Jr. Activation of human polymor-phonuclear neutrophil functions by interferon-gamma and tumour necrosis factor. J Immunol. 1985;135:2069–2073.
22. Lindemann A., Herrmann F., Oster W. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood. 1989;74:2644–2651.
23. Beutler B., Kronchin N., Milsark I.W., Luedke C., Cerami A. Control of cachectin (tumour necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 1986;232:977–980. doi: 10.1126/science.3754653.
24. Dinarello C.A., Cannon J.G., Wolff S.M. New concepts on the pathogenesis of lever. Rev Infect Dis. 1988;10:168–189. doi: 10.1093/clinids/10.1.168.
25. Butler L.D., Layman N.K., Cain R.L. Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention. Clin Immunol Immunopathol. 1989;53:400–421. doi: 10.1016/0090-1229(89)90003-2.
26. Zuckerman S.H., Shelhaas J., Butler L.D. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumour necrosis factor synthesis: the effects of endogenous gl glucocorticosteroids and the role of pituitary-adrenal access. Eur J Immunol. 1989;19:301–305. doi: 10.1002/eji.1830190213.
27. Lefer A.M. Induction of tissue injury and altered cardiovascular performance by platelet-activating factor: relevance to multiple systems organ failure. Crit Care Clin. 1989;5:331–351.
28. Utsumi K., Takai Y., Tada T. Enhanced production of IL-6 in tumour-bearing mice and determination of cells responsible for its augmented production. J Immunol. 1990;145:397–403.
29. Vane J.R., Anggard E.E., Botting R.M. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27–36. doi: 10.1056/NEJM199007053230106.
30. Dinerman J.L., Mehta J.L. Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance. J Am Coll Cardiol. 1990;16:207–222. doi: 10.1016/0735-1097(90)90481-4.
31. Deitch E.A. Multiple organ failure: pathophysiology and potential future therapy. Ann Surg. 1992;216:117–131. doi: 10.1097/00000658-199208000-00002.
32. Arai K., Lee F., Miyajima A. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem. 1990;59:783–836. doi: 10.1146/annurev.bi.59.070190.004031.
33. Crawford J., Ozer H., Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med. 1991;325:164–170. doi: 10.1056/NEJM199107183250305.
34. Nemunaitis J., Rabinowe S.N., Singer J.W. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773–1778. doi: 10.1056/NEJM199106203242504.
35. Sheridan W.P., Morstyn G., Wolfe M. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet. 1989;2:891–895. doi: 10.1016/s0140-6736(89)91552-3.
36. Gianni A.M., Siena S., Bregni M. Granulocyte-macrophage colony-stimulating factor to harvest circulating hemoatopoietic stem cells for autotransplantation. Lancet. 1989;2:580–585. doi: 10.1016/s0140-6736(89)90711-3.
37. Sheridan W.P., Begley C.G., Juttner C.A. Effective peripheral-blood progenitor cells mobilized by filgrastin (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992;339:640–644. doi: 10.1016/0140-6736(92)90795-5.
38. Dale D.C., Hammond W.P., Gabrilove J. Long-term treatment of severe chronic neutropenia with recombinant human granulocyte factor (r-metHuG-CSF) Blood. 1990;76(suppl 1):139. abstract.
39. Hammond W.P., Price T.H., Souza L.M., Dale D.C. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med. 1989;320:1306–1311. doi: 10.1056/NEJM198905183202003.
40. Migliaccio A.R., Migliaccio G., Dale D.C., Hammond W.P. Hematopoietic progenitors in cyclic neutropenia: the effect of granulocyte colony-stimulating factor in vivo. Blood. 1990;75:1951–1959.
41. Miles S.A., Mitsuyasu R.T., Morano J. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietic decreases hematologic toxicity from zidovudine. Blood. 1991;77:2109–2117.
42. Pluda J.M., Yarchoan R., Smith P.D. Subcutaneous recombinant granulocyte macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood. 1990;76:463–472.
43. Perno C.F., Yarchoan R., Cooney D.A. Replication of human immunodeficiency virus in monocytes: granulocytes/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′azido-2′-3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med. 1989;169:933–951. doi: 10.1084/jem.169.3.933.
44. Nelson S. The effects of thermal injury on systematic and pulmonary host defences. Crit Care Rep. 1991;2:241–253.
45. Mooney D.P., Gamelli R.L., O'Reilly M., Hebert J.C. Recombinant human granulocyte colony-stimulating factor and burn Pseudomonas wound sepsis. Arch Surg. 1988;123:1353–1357. doi: 10.1001/archsurg.1988.01400350067010.
46. Silver G.M., Gamelli R.L., O'Reilly M. The beneficial effect of granulocyte colony-stimulating factory (G-CSF) in combination with gentamycin on survival after Pseudomonas burn wound infection. Surgery. 1989;106:452–456.
47. Cairo M.S., Mauss D., Kommareddy S. Prophylactic or simultaneous administration of recombinant human granulocyte colony-stimulating factor in the treatment of group B streptococcal sepsis in neonatal rats. Pediatr Res. 1990;27:612–616. doi: 10.1203/00006450-199006000-00016.
48. O'Reilly M., Silver G.M., Greenhalgh D., Gamelli R.L., Davis J.H., Hebert J.C. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma. 1992;33:679–682. doi: 10.1097/00005373-199211000-00014.
49. Hebert J.C., O'Reilly M., Gamelli R.L. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg. 1990;125:1075–1078. doi: 10.1001/archsurg.1990.01410200141022.
50. Nelson S., Summer W., Bagby G. Granulocyte colony-stimulating factor enhances pulmonary host defences in normal and ethanol-treated rats. J Infect Dis. 1991;164:901–906. doi: 10.1093/infdis/164.5.901.
51. Silberstein D.S., David J.R. The regulation of human eosinophil function by cytokines. Immunol Today. 1987;8:380–384. doi: 10.1016/0167-5699(87)90214-3.
52. Cheers C., Haigh A.M., Kelso A. Production of colony-stimulating factors during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSF's. Infect Immun. 1988;56:247–251. doi: 10.1128/iai.56.1.247-251.1988.
53. Antman K.S., Griffin J.D., Elias A. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988;319:593–598. doi: 10.1056/NEJM198809083191001.
54. Nelson S., Mason C., Bagdy G. Effect of murine recombinant granulocyte-macrophage colony-stimulating factor on lipopolysaccharide-induced tumour necrosis factor. Am Rev Respir Dis. 1990;141:677. S.
55. Sisson S.D., Dinarello C.A. Production of interleukin-1 alpha, interleukin-1 beta, and tumour necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood. 1988;72:1368–1374.
56. Atkins E. Pathogenesis of fever. Physiol Rev. 1960;40:580–646. doi: 10.1152/physrev.1960.40.3.580.
57. Saklatvala J., Sarfield S.J., Townsend Y. Pig interleukin-1: purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med. 1985;162:1208–1222. doi: 10.1084/jem.162.4.1208.
58. Dewhirst F.E., Stashenko P.P., Mole J.E., Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin-1 beta. J Immunol. 1985;135:2562–2568.
59. Moore M.A., Warren D.J. ed 3. Vol. 84. 1987. Synergy of interleukin-1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice; pp. 7134–7138. (Proc Natl Acad Sci USA).
60. Mori S., Goto K. Cloning and sequence analysis of cDNA for lymphocyte proliferation potentiating factor of rabbit neutrophils: identification as rabbit interleukin-1b. Biochem Biophys Res Comm. 1988;150:1237–1243. doi: 10.1016/0006-291x(88)90761-9.
61. Fryling C., Dombalagian M., Burgess W. Purification and characterization of tumour inhibitory factor-2: its identity to interleukin-1. Cancer Res. 1989;49:3333–3337.
62. Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627–1652.
63. Fibbe W.E., Schaafsma R., Falkenburg J.H.F., Willemze R. The biological activities of interleukin-1. Blut. 1989;59:147–156. doi: 10.1007/BF00320059.
64. Dinarello C.A., Ikejima T., Warner S.J. Interleukin-1 induces interleukin. I. Induction of circulating interleukin-1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol. 1987;139:1902–1910.
65. Warner S.J.C., Auger K.R., Libby P. Interleukin-1 induces interleukin-1. II. Interleukin-1 induces production of interleukin-1 by adult human vascular endothelial cells in vitro. J Immunol. 1987;139:1911–1917.
66. Sisson S.D., Dinarello C.A. Production of interleukin-1 alpha, interleukin-1 beta and tumour necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood. 1990;75:1895–1896.
67. Dinarello C.A., Cannon J.G., Wolff S.M. Tumour necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med. 1986;163:1433–1450. doi: 10.1084/jem.163.6.1433.
68. Ghezzi P., Dinarello C.A. IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-gamma. J Immunol. 1988;140:4238–4244.
69. Moore K.W., Vieira P., Fiorentino D.F. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 1990;248:1230–1234. doi: 10.1126/science.2161559.
70. Smith J., Urba W., Steis R. Interleukin-1 alpha: results of a phase I toxicity and immunomodulatory trial. Am Soc Clin Oncol. 1990;9:717.
71. Tewari A., Buhles W.C., Jr., Stranes H.F., Jr. Preliminary report: effects of interleukin-1 on platelet counts. Lancet. 1990;336:712–714. doi: 10.1016/0140-6736(90)92206-w.
72. Neta R., Douches S.D., Oppenheim J.J. Interleukin-1 as a radioprotector. J Immunol. 1986;136:2483–2485.
73. Fibbe W.E., Van der Meer J.W.M., Falkenburg J.H.F. A single low dose of human recombinant interleukin-1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp Haematol. 1989;17:229–234.
74. Van der Meer J.W.M., Barza M., Wolff S.M., Dinarello C.A. ed 3. Vol. 85. 1988. A low dose of recombinant interleukin-1 protects granulocytopenic mice from lethal Gram-negative infection; pp. 1620–1623. (Proc Natl Acad Sci USA).
75. Fibbe W.E., Falkenburg J.H.F., Schaafsma M.R., Willemze R. The hematopoietic activities of interleukin-1. Biotherapy. 1989;1:263–271. doi: 10.1007/BF02171002.
76. McNiece I., Langely K., Zsebo K. Recombinant human stem cell factor synergizes with CSF's and EPO to stimulate colony formulation of myeloid and erythroid cells. Blood. 1990;76:154a. (Abstr suppl)
77. Neta R., Sztein M.B., Oppenheim J.J. The in vivo effects of interleukin-1. Bone marrow cells are induced to cycle after administration of interleukin-1. J Immunol. 1987;139:1861–1866.
78. Gasparetto C., Laver J., Abboud M. Effect of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model. Blood. 1989;74:547–550.
79. Wallach D., Holtmann H., Engelmann H., Nophar Y. Sensitization and desensitization to lethal effects of tumour necrosis factor and IL-1. J Immunol. 1988;140:2994–2999.
80. Ye K., Koch K.C., Clark B.D., Dinarello C.A. Interleukin-1 beta down regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression. Immunology. 1992;75:427–434.
81. Mrosovsky N., Molony L.A., Conn C.A., Kluger M.J. Anorexic effects of interleukin-1 in the rat. Am J Physiol. 1989;257:R1315. doi: 10.1152/ajpregu.1989.257.6.R1315.
82. Gershenwald J.E., Fong Y.M., Fahey T.J., III . ed 3. Vol. 87. 1990. Interleukin-1 receptor blockade attenuates the host inflammatory response; pp. 4966–4970. (Proc Natl Acad Sci USA).
83. Okusawa S., Gelfand J.A., Ikejima T. Interleukin-1 induces a shock-like state in rabbits. Synergism with tumour necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988;81:1162–1172. doi: 10.1172/JCI113431.
84. Rothenberg E.V., Diamond R.A., Pepper K.A., Yang J.A. IL-2 inducibility in T cells before T cell receptor expression. J Immunol. 1990;144:1614–1624.
85. Kurt-Jones E.A., Beller D.I., Mizel S.B. ed 3. Vol. 82. 1985. Identification of a membrane-associated interleukin-1 in macrophages; pp. 1204–1208. (Proc Natl Acad Sci USA).
86. Fong Y., Tracey K.J., Moldawer L.L. Antibodies to cachetin/tumour necrosis factor reduce interleukin-1 beta and interleukin-6 appearance during lethal bacteremia. J Exp Med. 1989;170:1627–1633. doi: 10.1084/jem.170.5.1627.
87. Neta R., Oppenheim J.J., Douches S.D. Interdependence of radioprotective effects of human recombinant interleukin-1 alpha, tumour necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony stimulating factor. J Immunol. 1988;140:108–111.
88. Chantry D., Turner M., Abney E., Feldman M. Modulation of cytokine production by transforming growth factor-beta. J Immunol. 1989;142:40–95.
89. Moreb J., Zucali J.R., Weiner R.S. The role of interleukin-3 and interleukin-6 and the protection from 4-hydroperoxy cyclophosphamide and the proliferation of early human hematopoietic progenitor cells. Exp Hematol. 1989;17:1022–1027.
90. Dinarello C.A., Rosenwasser L.J., Wolff S.M. Demonstration of circulating supressor factor of thymocyte proliferation during endotoxin fever in humans. J Immunol. 1981;127:2517–2519.
91. Liao Z., Grimshaw R.S., Rosenstreich D.L. Identification of a specific interleukin-1 inhibitor in the urine of febrile patients. J Exp Med. 1984;159:126–136. doi: 10.1084/jem.159.1.126.
92. Seckinger P., Dayer J.M. Interleukin-1 inhibitors. Ann Inst Pasteur Immunol. 1987;138:486–488. doi: 10.1016/s0769-2625(87)80063-6.
93. Balavoine J.F., De Rochemonteix B., Williamson K. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin-1 and inhibitor(s) J Clin Invest. 1986;78:1120–1124. doi: 10.1172/JCI112669.
94. Ohlsson K., Bjork P., Bergenfeldt M. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990;348:550–552. doi: 10.1038/348550a0.
95. Cominelli F., Nast C.C., Clark B.D. Interleukin-1 gene expression, synthesis and effective specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest. 1990;86:972–980. doi: 10.1172/JCI114799.
96. Ziegler E.J., McCutchan J.A., Fierer J. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982;307:1225–1230. doi: 10.1056/NEJM198211113072001.
97. Baumgartner J.-D., Glauser M.P., McCutchan J.A. Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet. 1985;2:59–63. doi: 10.1016/s0140-6736(85)90176-x.
98. Cornelissen J.J., Van Kessel C.P., Brouwer E., Kraaijeveld C.A., Verhoef J. Inhibition of lipid A-specific monoclonal antibodies by priming of human polymorphonuclear leucocytes by endotoxin. J Med Microbiol. 1991;34:233–238. doi: 10.1099/00222615-34-4-233.
99. Burd R.S., Cody C.S., Raymond C.S., Dunn D.L. Anti-endotoxin monoclonal antibodies protect by enhancing bacterial and endotoxin clearance. Arch Surg. 1993;128:145–150. doi: 10.1001/archsurg.1993.01420140022004.
100. Krieger J.I., Fletcher R.C., Siegel S.A. Human anti-endotoxin antibody HA-1A mediates complement-dependent binding of Escherichia coli J5 lipopolysaccharide to complement receptor type 1 of human erythrocytes and neutrophils. J Infect Dis. 1993;167:865–875. doi: 10.1093/infdis/167.4.865.
101. Cody C.S., Burd R.S., Mayoral J.L., Dunn D.L. Protective anti-lipopolysaccharide monoclonal antibodies inhibits tumour necrosis factory production. J Surg Res. 1992;52:314–319. doi: 10.1016/0022-4804(92)90109-d.
102. Wortel C.H., von der Mohlen M.A., van Deventer S.J. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in Gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis. 1992;166:1367–1374. doi: 10.1093/infdis/166.6.1367.
103. McCabe W.R., De Maria A., Jr., Berberich H., Johns M.A. Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (RE chemotype) mutant. J Infect Dis. 1988;158:291–300. doi: 10.1093/infdis/158.2.291.
104. Teng N.N.H., Kaplan H.S., Hebert J.M. ed 3. Vol. 82. 1985. Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies; pp. 1790–1794. (Proc Natl Acad Sci USA).
105. Siegel S.A., Evans M.E., Pollack M. Antibiotics enhanced binding by human lipid A-reactive monoclonal antibody HA-1A to smooth Gram-negative bacteria. Infect Immun. 1993;61:512–519. doi: 10.1128/iai.61.2.512-519.1993.
106. Ziegler E.J., Teng N.N.H., Douglas H. Treatment of pseudomonas bacteremia in neutropenic rabbits with human monoclonal IgM antibody against E. coli lipid A. Clin Res. 1987;35:619A. abstract.
107. Ziegler E.J. Protective antibody to endotoxin core: the emperor's new clothes? J Infect Dis. 1988;158:286–290. doi: 10.1093/infdis/158.2.286.
108. Quezado Z.M., Natanson C., Alling D.W. A controlled trial of HA-1A in a canine model of Gram-negative septic shock. JAMA. 1993:2221–2227.
109. Calandra T., Glauser M.P., Schellekens J., Verhoef J. Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective double-blind randomized trial. J Infect Dis. 1988;158:312–319. doi: 10.1093/infdis/158.2.312.
110. Khazaeli M.B., Wheeler R., Teng N. Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans. J Biol Response Mod. 1990;9:178–184.
111. Fisher C.J., Jr., Zimmerman J., Khazaeli M.B. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. Crit Care Med. 1990;18:1311–1315. doi: 10.1097/00003246-199012000-00001.
112. Ziegler E.J., Fisher C.J., Sprung C.L. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991;324:429–436. doi: 10.1056/NEJM199102143240701.
113. Siegel J.P., Stein K.E., Zoon K.C. Anti-endotoxin monoclonal antibodies. N Engl J Med. 1992;327:890–891.
114. Wolff S.M. Monoclonal antibodies and the treatment of Gram-negative bacteremia and shock. N Engl J Med. 1991;324:486–487. doi: 10.1056/NEJM199102143240709.
115. Tanio C.P., Feldman H.I. The HA-1A monoclonal antibody for Gram-negative sepsis (letter) N Engl J Med. 1991;324:280. doi: 10.1056/NEJM199107253250411.
116. Schulman K.A., Glick H.A., Reuben H., Eisenberg J.M. Cost-effectiveness of HA-1A monoclonal antibody for Gram-negative sepsis. Economic assessment of a new therapeutic agent. JAMA. 1991;266:3466–3471.
117. Greenman R.L., Schein R.M., Martin M.A. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991;266:1097–1102.
118. Romulo R.L., Palardy J.E., Opal S.M. Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. J Infect Dis. 1993;167:126–130. doi: 10.1093/infdis/167.1.126.
119. Wenzel R.P., Andriole V.T., Bartlett J.G. Antiendotoxin monoclonal antibodies for Gram-negative sepsis: guidelines from the IDSA. Clin Infect Dis. 1992;14:973–976. doi: 10.1093/clinids/14.4.973.
120. ed 3. Vol. 8. Department of Health and Human Services; Bethesda, MD: 1990. Intravenous immunoglobulin: prevention and treatment of disease. (NIH Consensus Development Conference. Consensus statement, May 21–23, 1990). No. 5.
121. Eibl M.M., Wedgwood R.J. Intravenous immunoglobulin: a review. Immunodefic Rev. 1989;1:1–42. (Suppl)
122. Lundblad J.L., Mitra G., Sternberg M.M., Schroeder D.D. Comparative studies of impurities in intravenous immunoglobulin preparations. Rev Infect Dis. 1986;8:S382–S390. doi: 10.1093/clinids/8.supplement_4.s382.
123. Zubler R.H. Antibody feedback regulation of the humoral immune response. In: Nydegger U.E., editor. Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy. Academic Press; New York: 1981. pp. 65–74.
124. Dwter J.M. Manipulating the immune system with immunoglobulin. N Engl J Med. 1992;326:107–116. doi: 10.1056/NEJM199201093260206.
125. Fehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med. 1982;306:1254–1258. doi: 10.1056/NEJM198205273062102.
126. Delfraissy J.F., Tchernia G., Laurian Y. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol. 1985;60:315–322. doi: 10.1111/j.1365-2141.1985.tb07417.x.
127. Bussel J., Pahwa S., Porges A. Correlation of in vitro antibody synthesis with outcome of intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. J Clin Immunol. 1986;6:50–56. doi: 10.1007/BF00915364.
128. Abdou M.I., Wall H., Lindsley H.B. Network theory in autoimmunity: in vitro suppression of serum anti-DNA antibody binding to DNA by antibody-ideotypic antibody in systemic lupus erythematosus. J Clin Invest. 1981;67:1297–1304. doi: 10.1172/JCI110158.
129. Bijsterbosch M.K., Klaus G.G.B. Cross-linking of surface immunoglobulin and Fc receptors on B-lymphocytes inhibits stimulation of inositol phospholipid breakdown via the antigen receptors. J Exp Med. 1985;162:1825–1836. doi: 10.1084/jem.162.6.1825.
130. Hahn B.H., Ebling R.M. Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody of anti-DNA. J Immunol. 1984;132:187–190.
131. Furusho K., Kamiya T., Nakano H. High-dose intravenous gamma-globulin for Kawasaki disease. Lancet. 1984;2:1055–1058. doi: 10.1016/s0140-6736(84)91504-6.
132. Newburger J.W., Takahashi M., Burns J.C. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341–347. doi: 10.1056/NEJM198608073150601.
133. Lekova E.S., Joffe L., Glode M.P. Antigenic recognition by intravenous gamma-globulin of selected bacteria isolated from throats of patients with Kawasaki syndrome. Pediatr Infect Dis J. 1990;9:620–623.
134. Leung D.Y.M., Burns J.C., Newburger J.W., Geha R.S. Reversal of lymphocytes activation in vivo in Kawasaki syndrome by intravenous gamma-globulin. J Clin Invest. 1987;79:468–472. doi: 10.1172/JCI112835.
135. Winston D.J., Pollard R.B., Ho W.G. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med. 1982;97:11–18. doi: 10.7326/0003-4819-97-1-11.
136. Condie R.M., O'Reilly R.J. Prevention of cytomegalovirus infection by prophylaxis with an intravenous hyperimmune, native, unmodified cytomegalovirus globulin. Am J Med. 1984;76:134–141. doi: 10.1016/0002-9343(84)90332-2.
137. Meyers J.D., Leszczynski J., Zaia J.A. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med. 1983;98:442–446. doi: 10.7326/0003-4819-98-4-442.
138. Bowden R.A., Sayers M., Flournoy M. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314:1006–1010. doi: 10.1056/NEJM198604173141602.
139. Emanuel D., Cunningham I., Jules-Elysee K. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with a combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777–782. doi: 10.7326/0003-4819-109-10-777.
140. Read E.C., Bowden R.A., Dandliker P.S. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109:783–788. doi: 10.7326/0003-4819-109-10-783.
141. Sullivan K.M., Kopecky K.J., Jocom A. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705–712. doi: 10.1056/NEJM199009133231103.
142. Snydman D.R., Werner B.G., Heinze-Lacey B. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987;317:1049–1054. doi: 10.1056/NEJM198710223171703.
143. Graneto D., Swift C., Steinmuller D.R. Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus (CMV) infection post-living-related donor renal transplantation (abstract 10). Abstracts of the American Society of Transplant Physicians Annual Meeting; Chicago; 1988.
144. Lederman H.M., Winkelstein J.A. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985;64:145–156.
145. Calvelli D.A., Rubinstein A. Intravenous gammaglobulin in infant acquired immunodeficiency syndrome. Pediatr Infect Dis. 1986;5:S207.
146. Siegel F.P., Oleske J. Management of the acquired immune deficiency syndrome: is there a role for immune globulins? In: Morell A., Nydegger U.E., editors. Clinical use of intravenous immunoglobulins. Academic Press; New York: 1986. pp. 387–394.
147. Schaad U.B. The role of IVIG in pediatric HIV infection. In: Imbach P., editor. Immunotherapy with intravenous immunoglobulins. Academic Press; London: 1991. pp. 201–209.
148. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991;325:73–80. doi: 10.1056/NEJM199107113250201.
149. Paryani S.G., Arvin A.M., Koropchak C.M. Comparison of varicella-zoster antibody titers in patients given intravenous immune serum globulin or varicella-zoster immune globulin. J Pediatr. 1984;105:200–205. doi: 10.1016/s0022-3476(84)80113-4.
150. Stevens D.A., Merigan T.C. Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. Arch Intern Med. 1980;140:52.
151. Hemming V.G., Rodriguez W., Kim H.W. Intravenous immunoglobulin treatment of respiratory syncytical virus infections in infants and young children. Antimicrob Agents Chemother. 1987;31:1882–1886. doi: 10.1128/aac.31.12.1882.
152. Crennan J.M., Van Scoy R.E., McKenna C.H., Smith T.F. Echovirus polymyositis in patients with hypogammaglobulinemia. Failure of high-dose intravenous gammaglobulin therapy and review of the literature. Am J Med. 1986;81:35–42. doi: 10.1016/0002-9343(86)90179-8.
153. Tobi M., Straus S.E. Chronic Epstein-Barr virus disease: a workshop held by the National Institute of Allergy and Infectious Diseases. Ann Intern Med. 1985;103:951–952. doi: 10.7326/0003-4819-103-6-951.
154. Lloyd A., Hickie I., Wakefield D. A double-blind placebo-controlled trial of intravenous immunoglobulin therapy patients with chronic fatigue syndrome. Am J Med. 1990;89:561–566. doi: 10.1016/0002-9343(90)90173-b.
155. Peterson P.K., Shepard J., Macres M. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med. 1990;89:554–560. doi: 10.1016/0002-9343(90)90172-a.
156. Ammann A.J., Hong R. Disorders of the T-cell system. In: Stiehm E.R., editor. Immunologic disorders in infants and children. ed 3. WB Saunders Co; Philadelphia: 1989. pp. 257–315.
157. Sidiropoulos D., Boehme U., Von Muralt G. Immunoglobulin supplementation in prevention or treatment of neonatal sepsis. Pediatr Infect Dis. 1986;5:S193.
158. Haque K.N., Zaidi M.H., Bahakim H. IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am J Dis Child. 1988;142:1293–1296. doi: 10.1001/archpedi.1988.02150120047038.
159. Munter A.M., Hoagland H.C., Pruitt B.A., Jr. The effect of thermal injury on serum immunoglobulins. Ann Surg. 1970;172:965–969. doi: 10.1097/00000658-197012000-00006.
160. Wesley J., Fisher M.W. Immunization against Pseudomonas in infection after thermal injury. J Infect Dis. 1974;130:S152–S158. doi: 10.1093/infdis/130.supplement.s152.
161. Stone H.H., Graber C.D., Martin J.D., Jr., Kolb L. Evaluation of a gamma globulin for prophylaxis against burn sepsis. Surgery. 1965;58:810–814.
162. Munster A.M., Moran K.T., Thupari J. Prophylactic intravenous immunoglobulin replacement in high-risk burn patients. J Burn Care Rehabil. 1987;8:376–380. doi: 10.1097/00004630-198709000-00007.
163. Winnie J.B., Cowan R.G., Wade N.A. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis. J Pediatr. 1989;114:309–314. doi: 10.1016/s0022-3476(89)80804-2.
164. Van Wye J.E., Collins M.S., Baylor M. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations of cystic fibrosis. Pediatr Pulmonol. 1990;9:7–18. doi: 10.1002/ppul.1950090104.
165. Silverstein A. History of immunology. Antibodies and anti-idiotypic regulation, 1899–1904. Cell Immunol. 1986;99:507. doi: 10.1016/0008-8749(86)90258-3.
166. Kunkel H.G., Mannik M., Williams R.C. Individual antigenic specificity of isolated antibodies. Science. 1963;140:1218–1219. doi: 10.1126/science.140.3572.1218.
167. Jerne N.K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974;125C:373–389.
168. Nisonoff A., Lamoyi E. Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies; possible application to vaccine production. Clin Immunol Immunopathol. 1981;21:397–406. doi: 10.1016/0090-1229(81)90228-2.
169. Roitt I.M., Male D.K., Guarnotta L.D. Idiotypic networks and their possible exploitation for manipulation of the immune response. Lancet. 1981;1:1041–1045. doi: 10.1016/s0140-6736(81)92199-1.
170. Nisonoff A. Idiotypes: concepts and applications. J Immunol. 1991;147:2429–2438.
171. Kennedy R.C., Eichberg J.W., Lanford R.E., Dreesman J.R. Anti-idiotypic antibody vaccine for type-B viral hepatitis in chimpanzees. Science. 1986;232:220–223. doi: 10.1126/science.3952505.
172. Thanavala Y.M., Roitt I.M. Monoclonal anti-idiotypic antibodies as surrogates for hepatitis B surface antigen. Int Rev Immunol. 1986;1:27–39. doi: 10.3109/08830188609056599.
173. Reagan K.J., Wunner W.H., Wiktor T.J., Koprowski H. Anti-idiotypic antibodies induce neutralizing antibodies to rabies virus glycoprotein. J Virol. 1983;48:660–666. doi: 10.1128/jvi.48.3.660-666.1983.
174. Gaulton G.M., Greene M.I. Idiotypic mimicry of biological receptors. Annu Rev Immunol. 1986;4:253–280. doi: 10.1146/annurev.iy.04.040186.001345.
175. Rolf J.M., Gauden H.M., Tirrell S.M., MacDonald A.B., Eidels L. Vol. 86. 1989. Anti-idiotypic antibodies that protect cells against the action of diphtheria toxin; p. 2036. (Proc Natl Acad Sci USA).
176. Rimmelzwaan G.F., Bunschoten E.J., Uytdehaag F.G., Osterhaus A.D. Monoclonal anti-idiotypic antibody vaccines against poliovirus, canine parvovirus and rabies virus. Methods Enzymol. 1989;178:375–390. doi: 10.1016/0076-6879(89)78028-9.
177. Zaghouani H., Goldstein D., Shah H. Vol. 88. 1991. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes; pp. 5645–5649. (Proc Natl Acad Sci USA).
178. Merigan T.C., Reed S.E., Hall T.S., Tyrrell D.A.J. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973;1:563–567. doi: 10.1016/s0140-6736(73)90714-9.
179. Scott G.M., Phillpotts R.J., Wallace J., Gauci C.L., Greiner J., Tyrrell D.A. Prevention of rhinovirus colds by human interferon-alpha2 from Escherichia coli. Lancet. 1982;2:186–188. doi: 10.1016/s0140-6736(82)91031-5.
180. Higgins P.G., Phillpotts R.J., Scott G.M., Wallace J., Bernhardt L.L., Tyrrell D.A.J. Intranasal interferon as protection against experimental respiratory Corona virus infection in volunteers. Antimicrob Agents Chemother. 1983;24:713–715. doi: 10.1128/aac.24.5.713.
181. Douglas R.M., Albrecht J.K., Miles H.B. Intrasanal interferon alpha-2 prophylaxis of natural respiratory infection. J Infect Dis. 1985;151:731–736. doi: 10.1093/infdis/151.4.731.
182. Hayden F.G., Gwaltney J.M., Jr., Johns E.M. Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha2 in natural respiratoty viral infections. Antiviral Res. 1985;5:111–116. doi: 10.1016/0166-3542(85)90037-3.
183. Hayden F.G., Albrecht J.K., Kaiser D.L., Gwaltney J.M., Jr. Prevention of natural colds by contact prophylaxus with intranasal alpha2-interferon. N Engl J Med. 1986;314:71–75. doi: 10.1056/NEJM198601093140202.
184. Douglas R.M., Moore B.W., Miles H.B. Prophylactic efficacy of intranasal alpha2-interferon against rhinovirus infections in the family setting. N Engl J Med. 1986;314:65–70. doi: 10.1056/NEJM198601093140201.
185. Merigan T.C., Jordan G.W., Fried R.P. Clinical utilization of exogenous human interferon. In: Pollard M., editor. Vol. 9. Academic Press; New York: 1975. pp. 249–264. (Antiviral Mechanisms (Perspectives in Virology)).
186. Greenberg H.B., Pollard R.B., Lutwick L.I., Gregory P.B., Robinson W.S., Merigan T.C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 1976;295:517–522. doi: 10.1056/NEJM197609022951001.
187. Jordan G.W., Fried R.P., Merigan T.C. Administration of human leukocyte interferon in herpes zoster I safety circulating antiviral activity, and host responses to infection. J Infect Dis. 1974;130:56–62. doi: 10.1093/infdis/130.1.56.
188. Hoofnagle J.H., Peters M., Mullen K.D. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology. 1988;95:1318–1325. doi: 10.1016/0016-5085(88)90367-8.
189. Perrillo R.P., Schiff E.R., Davis G.L. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295–301. doi: 10.1056/NEJM199008023230503.
190. Bisceglie A.M., Martin P., Kassianides C. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–1510. doi: 10.1056/NEJM198911303212204.
191. Davis G.L., Balart L.A., Schiff E.R. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicentre randomized, controlled trial. N Engl J Med. 1989;321:1501–1506. doi: 10.1056/NEJM198911303212203.
192. Lane H.C., Davey V., Kovacs J.A. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med. 1990;112:805–811. doi: 10.7326/0003-4819-112-11-805.
193. Krown S.E., Gold J.W.M., Niedzwiecki D. Interferon-α with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi's sarcoma associated with acquired immunodeficiency syndrome (AIDS) Ann Intern Med. 1990;112:812–821. doi: 10.7326/0003-4819-112-11-812.
194. Carter W.A., Brodsky I., Pellegrino M.G. Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet. 1987;7:1286–1292. doi: 10.1016/s0140-6736(87)90543-5.
195. Kovacs J.A., Deyton L., Davey R. Combined zidovudine and interferon-α therapy in patients with Kaposi's sarcoma and acquired immunodeficiency syndrome (AIDS) Ann Intern Med. 1989;111:280–287. doi: 10.7326/0003-4819-111-4-280.
196. Zagury D., Bernard J., Cheynier R. A group specific anamnestic immune reactive against AIDS. Nature. 1988;332:728–734. doi: 10.1038/332728a0.
197. Zarling J., Morton P.A., Moran P.A., McClure J., Kosowski S.G., Hu S.L. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia virus. Nature. 1986;323:344–346. doi: 10.1038/323344a0.
198. Furukawa K., Lotzova E., Freedman R.S., Bowen J.B., Edwards C.L., Wharton J.T. Effect of virus-modified tumour cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer. Cancer Immunol Immunother. 1989;30:126–132. doi: 10.1007/BF01665964.
199. Berman P.W., Gregory T.J., Riddle L. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp 120 but not gp 160. Nature. 1990;345:622–625. doi: 10.1038/345622a0.
200. Jackson G.G., Rubenis M., Knigge M. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet. 1988;9:647–652. doi: 10.1016/s0140-6736(88)90468-0.
201. Zolla-Pazner S., Pinter A., Mizuma H. Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus. J Virol Meth. 1987;17:45–53. doi: 10.1016/0166-0934(87)90067-x.
202. Javaherian K., Langlois A.J., McDanal C. Vol. 86. 1989. Principle neutralizing domaine of the human immunodeficiency virus type 1 envelope protein; pp. 6768–6772. (Proc Natl Acad Sci USA).
203. Smith D.H., Bryn R.A., Marsters S.A., Gregory T., Groopman J.E., Capon D.J. Blocking of HIV-1 infectivity by a soluble, secreted form of CD4 antigen. Science. 1987;238:1704–1707. doi: 10.1126/science.3500514.
204. Bryn R.A., Mordenti J., Lucas C. Biological properties of a CD4 immunoadhesin. Nature. 1990;344:667–670. doi: 10.1038/344667a0.
205. Ashorn P., Moss B., Weinstein J.N. Vol. 87. 1990. Elimination of infectious human immunodeficiency virus from human T-cell cultures, by synergistic action of CD4 pseudomonas exotoxin and reverse transcriptase inhibitors; pp. 1–5. (Proc Natl Acad Sci USA).
206. Barcellini W., Meroni P.L., Frasca D. Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy. Clin Exp Immun. 1987;67:537–543.
207. Silvestris F., Gernone A., Frassanito M., Dammacco F. Immunologic effect of long-term thymopentin treatment in patients with HIV-induced lymphadenopathy syndrome. J Lab Clin Med. 1989;113:139–144.
208. Pedersen C., Sandstrom E., Peterson C.S. The efficacy of inosine paranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med. 1990;322:1757–1763. doi: 10.1056/NEJM199006213222501.
209. Reisinger E.C., Kern P., Ernst M. Inhibition of HIV progression by ditiocarb. Lancet. 1990;335:679–682. doi: 10.1016/0140-6736(90)90802-c.
210. Hersh E.M., Brewton G., Abrams D. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized double-blind placebo-controlled multicentre study. J Am Med Assoc. 1991;265:1538–1544.
211. Patt Y.Z., Hersh E.M., Reuben J.M., Claghorn L., Mavligit G.M. A phase I study of intravenous azimexon therapy in human cancer. J Biol Resp Mod. 1986;5:313–318.
212. Haranaka K., Satomi N., Sakurai A. Anti-tumor activities and tumor necrosis factor producibility of traditional Chinese medicines in crude drugs. Cancer Immunol Immunother. 1985;20:1–5. doi: 10.1007/BF00199765.
213. Satomi N., Sakurai A., Haranaka R., Haranaka K. The influence of antibiotics on the host-parasite relationship. Springer-Verlag; Berlin: 1988. Traditional Chinese medicines and drugs in relation to the host-defence mechanism; pp. 77–86.
214. Kono H., Ohara M., Odajima S., Yamaguchi N. The effect of Saikosaponin on immune response. J Med Pharmacol Soc Wakan-Yaka. 1985;2:85–89.
215. Iwama H., Amagaya, Ogihara Y. Studies of the combined use of steroid and Shosaiko-to, one of the Kanpohoza (Chinese traditional medicine), on pituitary adrenal cortical space axis funstion and immune responses. J Pharmacobiodyn. 1986;9:189–196. doi: 10.1248/bpb1978.9.189.